Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform
UPPSALA, Sweden, Dec. 2, 2021 /PRNewswire/ — Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions. Adrenaline is commonly used for the…
Comments Off on Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform